+关注
xygn
暂无个人介绍
IP属地:未知
16
关注
3
粉丝
0
主题
0
勋章
主贴
热门
xygn
2021-11-18
Sad
Wall Street ends lower as retailers stoke inflation fears
xygn
2021-11-13
Buyyyyy
Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.
xygn
2021-11-15
Latest
Retail sales, Walmart and Target earnings: What to know this week
xygn
2021-10-22
Great
抱歉,原内容已删除
xygn
2021-12-23
Ok
Rivian vs. Ford: Which Is the Better Buy?
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3581560135544218,"uuid":"3581560135544218","gmtCreate":1618466111376,"gmtModify":1618466111376,"name":"xygn","pinyin":"xygn","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":16,"tweetSize":43,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖(非转发)","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.62%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":691432647,"gmtCreate":1640226400337,"gmtModify":1640226400421,"author":{"id":"3581560135544218","authorId":"3581560135544218","name":"xygn","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691432647","repostId":"1119859400","repostType":4,"repost":{"id":"1119859400","pubTimestamp":1640226140,"share":"https://www.laohu8.com/m/news/1119859400?lang=&edition=full","pubTime":"2021-12-23 10:22","market":"us","language":"en","title":"Rivian vs. Ford: Which Is the Better Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=1119859400","media":"InvestorPlace","summary":"Rivian has great potential, but is it a better buy than something like Ford?","content":"<p><b>Rivian</b>(NASDAQ:<b><u>RIVN</u></b>) recently hit new lows on Dec. 17 after reporting earnings. RIVN stock fell 10% as a result of a top- and bottom-line miss, the company’s first report as a public company.</p>\n<p>Even with the drop, Rivian commands a market capitalization of $84 billion. That’s more than <b>Ford</b>(NYSE:<b><u>F</u></b>) and <b>General Motors</b>(NYSE:<b><u>GM</u></b>). That’s crazy!</p>\n<p>The valuation with electric vehicle (EV) stocks has gone bananas.</p>\n<p>In the pre-EV days, automakers were assigned insultingly low valuations. Perhaps we’re in the midst of a great “rerating” in terms of valuation, but building EVs vs. traditional internal combustion engine (ICE) vehicles<i>shouldn’t</i>create such disparity with the valuation.</p>\n<p>That’s where we find ourselves though, as investors wonder if this shift is permanent or temporary.</p>\n<p>I don’t have anything personal against RIVN stock, but I personally find its valuation to be too high. Shares trade at about 10.4 times 2023 estimates, estimates of which may very well may be too optimistic in the first place.</p>\n<p>That’s got me comparing it to other automakers, namely Ford.</p>\n<p><b>RIVN Stock vs. F Stock</b></p>\n<p>Rivian does not generate meaningful revenue at the moment, although it does have a partnership with <b>Amazon</b>(NASDAQ:<b><u>AMZN</u></b>). The latter also owns a 20% stake in the company, for what it’s worth.</p>\n<p>Estimates currently call for $3.45 billion in sales next year for Rivian, although that estimate is at risk (in my opinion) as management has said supply chain issues could negatively impact deliveries. On the plus side, there are 71,000 RI reservations for its new vehicle.That’s up 48% in the last two and a half months.</p>\n<p>But then you flip around to Ford and ask yourself, “If Rivian is worth $84 billion, why is Ford only worth $80 billion?”</p>\n<p>The company is forecast to generate ~$127 billion in sales in 2021, up 9.5% year over year. In 2022 and 2023, estimates sit at $145.3 billion and $164 billion, respectively.</p>\n<p>The latter figure is almost 20 times larger than the $8.4 billion Rivian is forecast to generate that year. Now that comparison is a bit like apples to oranges, but it highlights the difference between these two companies and what stage they are at.</p>\n<p>Rivian is like the kid that walked into the office and was promoted to VP on their first day. Ford has been there for 30 years and still can’t make partner.</p>\n<p><b>Truck vs. Truck</b></p>\n<p>Ford is making a serious transition toward EVs. It already has its Mustang Mach E on the road, with the E-Transit on the way. Ford even has a pilot program to help companies integrate the E-Transit into their fleets.</p>\n<p>But the crown jewel is the F-150 Lightning.</p>\n<p>The F-Series pickup truck is the best selling<i>vehicle</i>in the U.S. and has been for more than four decades. While Rivian has an impressive 71,000 reservations, Ford stopped taking reservations for its F-150 Lightning, as the list topped 200,000.</p>\n<p>Demand is clearly through the roof here. While that has many investors optimistic on the future of EV and specifically on Rivian, why don’t they see the competition that’s coming down the pike?</p>\n<p>It would be one thing if Rivian was going to enter the electric pickup truck market with no competition. But the fact that it’s fighting the electrification of the country’s best-selling pickup and vehicle,andgoing up against<b>Tesla</b>(NASDAQ:<b><u>TSLA</u></b>), GM and others, should have investors asking some questions.</p>\n<p>Namely this: Is RIVN stock overvalued or is F stock undervalued — or is it both?</p>\n<p>Granted, the R1T has a better EPA-estimated driving range for its base model than the base model for Ford’s Lightning. That said, Ford’s electric pickup starts at around $40,000 and can get an upgrade to its range, while the R1T has a starting price of roughly $67,500.</p>\n<p>Ford expects to “increase its production capacity of electric vehicles to 600,000 units globally by 2023.” Further, CEO Jim Farley “expects that would make the company the second-largest U.S.-based producer of EVs,” just behind <b>Tesla</b>(NASDAQ:<b><u>TSLA</u></b>).</p>\n<p>For what it’s worth, General Motors will likely be in that mix as well, with management previously stating it expects to produce 1 million EVs by 2025.</p>\n<p><b>Bottom Line on RIVN Stock</b></p>\n<p>I must repeat again that I don’t have anything personal against Rivian. I actually really like EVs and autonomous driving systems and I covered the space for years.</p>\n<p>But the sudden fascination with this industry — shown via the valuations — has me asking some questions as to how it’s justified. For now, I still don’t have the answer and, between the two stocks, I’d rather be long Ford at these levels than RIVN stock.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rivian vs. Ford: Which Is the Better Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRivian vs. Ford: Which Is the Better Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 10:22 GMT+8 <a href=https://investorplace.com/2021/12/rivian-rivn-stock-vs-ford-which-is-the-better-buy/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Rivian(NASDAQ:RIVN) recently hit new lows on Dec. 17 after reporting earnings. RIVN stock fell 10% as a result of a top- and bottom-line miss, the company’s first report as a public company.\nEven with...</p>\n\n<a href=\"https://investorplace.com/2021/12/rivian-rivn-stock-vs-ford-which-is-the-better-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"F":"福特汽车","RIVN":"Rivian Automotive, Inc."},"source_url":"https://investorplace.com/2021/12/rivian-rivn-stock-vs-ford-which-is-the-better-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1119859400","content_text":"Rivian(NASDAQ:RIVN) recently hit new lows on Dec. 17 after reporting earnings. RIVN stock fell 10% as a result of a top- and bottom-line miss, the company’s first report as a public company.\nEven with the drop, Rivian commands a market capitalization of $84 billion. That’s more than Ford(NYSE:F) and General Motors(NYSE:GM). That’s crazy!\nThe valuation with electric vehicle (EV) stocks has gone bananas.\nIn the pre-EV days, automakers were assigned insultingly low valuations. Perhaps we’re in the midst of a great “rerating” in terms of valuation, but building EVs vs. traditional internal combustion engine (ICE) vehiclesshouldn’tcreate such disparity with the valuation.\nThat’s where we find ourselves though, as investors wonder if this shift is permanent or temporary.\nI don’t have anything personal against RIVN stock, but I personally find its valuation to be too high. Shares trade at about 10.4 times 2023 estimates, estimates of which may very well may be too optimistic in the first place.\nThat’s got me comparing it to other automakers, namely Ford.\nRIVN Stock vs. F Stock\nRivian does not generate meaningful revenue at the moment, although it does have a partnership with Amazon(NASDAQ:AMZN). The latter also owns a 20% stake in the company, for what it’s worth.\nEstimates currently call for $3.45 billion in sales next year for Rivian, although that estimate is at risk (in my opinion) as management has said supply chain issues could negatively impact deliveries. On the plus side, there are 71,000 RI reservations for its new vehicle.That’s up 48% in the last two and a half months.\nBut then you flip around to Ford and ask yourself, “If Rivian is worth $84 billion, why is Ford only worth $80 billion?”\nThe company is forecast to generate ~$127 billion in sales in 2021, up 9.5% year over year. In 2022 and 2023, estimates sit at $145.3 billion and $164 billion, respectively.\nThe latter figure is almost 20 times larger than the $8.4 billion Rivian is forecast to generate that year. Now that comparison is a bit like apples to oranges, but it highlights the difference between these two companies and what stage they are at.\nRivian is like the kid that walked into the office and was promoted to VP on their first day. Ford has been there for 30 years and still can’t make partner.\nTruck vs. Truck\nFord is making a serious transition toward EVs. It already has its Mustang Mach E on the road, with the E-Transit on the way. Ford even has a pilot program to help companies integrate the E-Transit into their fleets.\nBut the crown jewel is the F-150 Lightning.\nThe F-Series pickup truck is the best sellingvehiclein the U.S. and has been for more than four decades. While Rivian has an impressive 71,000 reservations, Ford stopped taking reservations for its F-150 Lightning, as the list topped 200,000.\nDemand is clearly through the roof here. While that has many investors optimistic on the future of EV and specifically on Rivian, why don’t they see the competition that’s coming down the pike?\nIt would be one thing if Rivian was going to enter the electric pickup truck market with no competition. But the fact that it’s fighting the electrification of the country’s best-selling pickup and vehicle,andgoing up againstTesla(NASDAQ:TSLA), GM and others, should have investors asking some questions.\nNamely this: Is RIVN stock overvalued or is F stock undervalued — or is it both?\nGranted, the R1T has a better EPA-estimated driving range for its base model than the base model for Ford’s Lightning. That said, Ford’s electric pickup starts at around $40,000 and can get an upgrade to its range, while the R1T has a starting price of roughly $67,500.\nFord expects to “increase its production capacity of electric vehicles to 600,000 units globally by 2023.” Further, CEO Jim Farley “expects that would make the company the second-largest U.S.-based producer of EVs,” just behind Tesla(NASDAQ:TSLA).\nFor what it’s worth, General Motors will likely be in that mix as well, with management previously stating it expects to produce 1 million EVs by 2025.\nBottom Line on RIVN Stock\nI must repeat again that I don’t have anything personal against Rivian. I actually really like EVs and autonomous driving systems and I covered the space for years.\nBut the sudden fascination with this industry — shown via the valuations — has me asking some questions as to how it’s justified. For now, I still don’t have the answer and, between the two stocks, I’d rather be long Ford at these levels than RIVN stock.","news_type":1},"isVote":1,"tweetType":1,"viewCount":440,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":878523618,"gmtCreate":1637209023073,"gmtModify":1637209023073,"author":{"id":"3581560135544218","authorId":"3581560135544218","name":"xygn","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Sad","listText":"Sad","text":"Sad","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":15,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/878523618","repostId":"2184510828","repostType":4,"isVote":1,"tweetType":1,"viewCount":1375,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3582839637303229","authorId":"3582839637303229","name":"vxf","avatar":"https://static.tigerbbs.com/b1ee9a28e0a19bf5b87d52e90dc87788","crmLevel":2,"crmLevelSwitch":0},"content":"大家好, 请随时查看我关于数字货币之旅的个人资料。 它只用于分享,简单的PDF,没有骗局。感谢&安培;祝你有愉快的一天。","text":"大家好, 请随时查看我关于数字货币之旅的个人资料。 它只用于分享,简单的PDF,没有骗局。感谢&安培;祝你有愉快的一天。","html":"大家好, 请随时查看我关于数字货币之旅的个人资料。 它只用于分享,简单的PDF,没有骗局。感谢&安培;祝你有愉快的一天。"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873595369,"gmtCreate":1636957479818,"gmtModify":1636957486626,"author":{"id":"3581560135544218","authorId":"3581560135544218","name":"xygn","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873595369","repostId":"2183536049","repostType":4,"repost":{"id":"2183536049","pubTimestamp":1636931077,"share":"https://www.laohu8.com/m/news/2183536049?lang=&edition=full","pubTime":"2021-11-15 07:04","market":"us","language":"en","title":"Retail sales, Walmart and Target earnings: What to know this week","url":"https://stock-news.laohu8.com/highlight/detail?id=2183536049","media":"Yahoo Finance","summary":"Investors this week will be focused on data on the consumer, with both retail sales and earnings results from two retail giants set for release.The total value of retail sales in the U.S. is expected to have climbed by 1.1% month-on-month in October, according to the Commerce Department's latest monthly print on Tuesday. This would accelerate from a 0.7% monthly advance in September, which had been an unexpected increase at the time given that many economists were anticipating that a rise in Del","content":"<p><img src=\"https://static.tigerbbs.com/08676f0472643b38e9d755d70877271b\" tg-width=\"1878\" tg-height=\"2390\" referrerpolicy=\"no-referrer\"></p>\n<p>Investors this week will be focused on data on the consumer, with both retail sales and earnings results from two retail giants set for release.</p>\n<p>The total value of retail sales in the U.S. is expected to have climbed by 1.1% month-on-month in October, according to the Commerce Department's latest monthly print on Tuesday. This would accelerate from a 0.7% monthly advance in September, which had been an unexpected increase at the time given that many economists were anticipating that a rise in Delta variant cases would weigh on spending during the month.</p>\n<p>\"Our data suggest broad-based improvement across major sectors, including restaurants, department stores and general merchandise,\" Bank of America economist Michelle Meyer wrote in a note on Friday. \"Netting out restaurants, gas and building materials, we look for the core control group to increase 0.5% [month-over-month]. Consumer spending remained resilient in October and will likely stay elevated as we head into the holiday season.\"</p>\n<p>If results come is as expected, October would mark a third straight monthly increase in retail sales. However, the rate of growth in consumer spending has slowed considerably in the second half of this year so far, compared to the first half when government stimulus checks and other economic support had helped pad consumers' wallets and stoke spending. The Bureau of Labor Statistics' last report on U.S. GDP showed that personal consumption slowed to a just 1.6% annualized rate in the third quarter, down from a 12.0% clip in the second.</p>\n<p>A jump in prices, as inflationary pressure reverberates across the recovering economy, is <a href=\"https://laohu8.com/S/AONE.U\">one</a> factor economists are closely watching as a potential anchor on consumer spending. While many companies have signaled in their latest earnings reports that they have been able to pass on prices to end users so far, consumers are beginning to take note of rising inflation. Depending on the magnitude and extent of the price increases, this could have a further dampening effect on consumption.</p>\n<p>The University of Michigan Surveys of Consumers highlighted last week that consumers expected inflation to rise by 4.9% over the next year, which was the highest print since 2008. And the headline index for the University of Michigan showed that the overall sentiment index fell to a 10-year low in early November, in large part reflecting concerns over how inflation would impact consumers' finances. This report came just two days after the Bureau of Labor Statistics' Consumer Price Index (CPI) for October showed that inflation jumped by a greater-than-expected 6.2% compared to the prior year, marking the fastest annual rise since 1990.</p>\n<p>\"It does take a while before a drop in consumer sentiment actually impacts spending,\" Yung-Yu Ma, BMO Wealth Management's chief investment strategist, told Yahoo Finance Live last week.</p>\n<p>\"That's going to be one of the big things going forward, to see whether or not that consumer sentiment can bounce back, whether consumers will be resilient in the face of these price pressures, or whether they'll start to pull back a bit and decide they're going to hold off on spending and wait to see when prices come down or at least stabilize before they spend more in the new year,\" he said. \"So that remains to be seen, and that is a big question mark as we go into 2022.\"</p>\n<h2>Big box retailers report earnings</h2>\n<p>Quarterly earnings results from companies including Walmart and Target will also be monitored this week as a proxy of consumers' propensity to spend, especially heading into the critical holiday shopping season. The results and earnings calls will also likely include more commentary around how shipping delays and supply chain disruptions are impacting America's largest retailers.</p>\n<p>A back-to-school season that saw many students return to class in-person likely helped stoke spending at both Walmart and Target. Growth still likely slowed compared to earlier on during the pandemic, however, when the companies had benefited from a consumer shift to spending on goods rather than on services, and to big-box stores that would allow them to get all their shopping needs done in one trip during the pandemic.</p>\n<p>Walmart's sales are expected to grow just 1% on a year-over-year basis to reach $135.5 billion, data from Bloomberg showed. This would mark the slowest top-line growth rate since the first quarter of 2020. Total Walmart U.S. same-store sales are expected to grow 7%, however, to accelerate from the prior quarter's 5.4% increase. Walmart U.S. operating margins are also expected to expand to 5.35%, compared to 5.2% in the same quarter last year, but may contract compared to the 6.2% margin posted in the second quarter this year.</p>\n<p><img src=\"https://static.tigerbbs.com/cc803a27e7a5de4f45494c90d84e6e2c\" tg-width=\"6720\" tg-height=\"4480\" referrerpolicy=\"no-referrer\">The logo of Walmart is seen outside of a new Walmart Store in San Salvador, El Salvador, August 21, 2018. REUTERS/Jose CabezasJose Cabezas / Reuters</p>\n<p>Already last quarter, Walmart executives highlighted during their last earnings call in August that \"out of stocks in certain general merchandise categories\" were \"running above normal given strong sales and supply constraints,\" presaging what many other companies have highlighted in their own earnings results in recent weeks. The firm added at the time that they were also taking steps to try and circumvent supply snarls, including chartering vessels specifically for Walmart goods. All these measures, however, also incur additional costs.</p>\n<p>Target, for its part, also mentioned it was trying to maneuver around supply chain disruptions on its latest earnings call as well.</p>\n<p>\"Our team has been successfully addressing supply chain bottlenecks, which are affecting both domestic freight and international shipping. Steps include expedited ordering and larger upfront quantities in advance of a season, mitigating the risk that replenishments could take longer than usual,\" said Target Chief Operating Officer John Mulligan in August. \"Bottom line, with Q2 ending inventory up more than 26% or nearly $2.5 billion compared to a year ago, we believe we're well-positioned for the fall and ready to deliver strong growth on top of last year's record increase.\"</p>\n<p>Target is expected to see revenue grow 8% to $24.09 billion in its fiscal third quarter, also slowing compared to its 9% growth rate in the second quarter and 21% year-over-year increase in the same period last year. Closely watched same-store sales are expected to rise b 8.3%, or slower than the 8.9% rate in the second quarter. Digital same-store sales, however, are anticipated to accelerate sequentially to a 13.25% clip, on top of the 155% digital sales growth Target posted in the same period last year.</p>\n<p>Commentary around labor supply shortages and hiring trends will also be closely watched for both Target and Walmart. In September, Target said it would be hiring 100,000 seasonal employees for the holidays, or fewer than the more than 130,000 workers it hired in each of the last two holiday seasons. It planned to instead provide more hours and pay to its slightly smaller holiday workforce this year.</p>\n<p>Walmart said in September it was planning to hire about 150,000 new U.S. store workers ahead of the holidays, with most of these comprising permanent and full-time roles.</p>\n<h2>Economic calendar</h2>\n<ul>\n <li><p><b>Monday: </b>Empire Manufacturing, Nov. (21.2 expected, 19.8 in prior print)</p></li>\n <li><p><b>Tuesday: </b>Retail sales advance, month-over-month, Oct. (1.1% expected, 0.7% in Sept.); Retail sales excluding autos and gas, month-over-month, Oct. (0.9% expected, 0.8% in Sept.); Import price index month-over-month, Oct. (1.0% expected, 0.4% in Sept.); Export price index, month-over-month, Oct. (0.9% expected, 0.1% in Sept.); Industrial Production, month-over-month, Oct. (0.9% expected, -1.3% in Sept.); Capacity Utilization, OCt. (75.9% expected, 75.2% in Sept.); NAHB Housing Market Index, Nov. (80 expected, 80 in Oct.)</p></li>\n <li><p><b>Wednesday: </b>MBA mortgage Applications, week ended Nov. 12 (5.5% during prior week); Building permits, month-over-month, Oct. (2.8% expected, -7.8% in Sept.); Housing starts, Oct. (1.6% expected, -1.6% in Sept.)</p></li>\n <li><p><b>Thursday: </b>Initial jobless claims, week ended Nov. 13 (260,000 expected, 267,000 during prior week); Continuing claims, week ended Nov. 6 (2.160. million during prior week); Philadelphia Fed Business Outlook, Nov. (24.0 expected, 23.8 in Sept.); Leading Index, Oct. (0.8% expected, 0.2% in Sept.); Kansas City Fed Manufacturing Activity Index, Nov. (31 in Oct.)</p></li>\n <li><p><b>Friday: </b><i>No notable reports scheduled for release</i></p></li>\n</ul>\n<h2>Earnings calendar</h2>\n<ul>\n <li><p><b>Monday:</b> Oatly (OTLY), <a href=\"https://laohu8.com/S/WE\">WeWork</a> (WE) before market open; Endeavor Group Holdings (EDR), Lucid Group (LCID) after market close</p></li>\n <li><p><b>Tuesday: </b>Home Depot (HD), Walmart (WMT) before market open</p></li>\n <li><p><b>Wednesday: </b>Lowe's (LOW), Target (TGT), TJX Cos. (TJX) before market open; Sonos (SONO), Nvidia (NVDA), Cisco (CSCO), Victoria's Secret (VSCO) after market close</p></li>\n <li><p><b>Thursday: </b>Kohl's (KSS), Macy's (M) before market open; Applied Materials (AMAT), Intuit (INTU), <a href=\"https://laohu8.com/S/WDAY\">Workday</a> (WDAY), <a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a> (PANW), Bath & Body Works (BBWI), Williams-Sonoma (WSM) after market close</p></li>\n <li><p><b>Friday: </b><i>No notable reports scheduled for release</i></p></li>\n</ul>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Retail sales, Walmart and Target earnings: What to know this week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRetail sales, Walmart and Target earnings: What to know this week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-15 07:04 GMT+8 <a href=https://finance.yahoo.com/news/retail-sales-and-retailers-earnings-what-to-know-this-week-154433076.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors this week will be focused on data on the consumer, with both retail sales and earnings results from two retail giants set for release.\nThe total value of retail sales in the U.S. is expected...</p>\n\n<a href=\"https://finance.yahoo.com/news/retail-sales-and-retailers-earnings-what-to-know-this-week-154433076.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite","TGT":"塔吉特","WMT":"沃尔玛"},"source_url":"https://finance.yahoo.com/news/retail-sales-and-retailers-earnings-what-to-know-this-week-154433076.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2183536049","content_text":"Investors this week will be focused on data on the consumer, with both retail sales and earnings results from two retail giants set for release.\nThe total value of retail sales in the U.S. is expected to have climbed by 1.1% month-on-month in October, according to the Commerce Department's latest monthly print on Tuesday. This would accelerate from a 0.7% monthly advance in September, which had been an unexpected increase at the time given that many economists were anticipating that a rise in Delta variant cases would weigh on spending during the month.\n\"Our data suggest broad-based improvement across major sectors, including restaurants, department stores and general merchandise,\" Bank of America economist Michelle Meyer wrote in a note on Friday. \"Netting out restaurants, gas and building materials, we look for the core control group to increase 0.5% [month-over-month]. Consumer spending remained resilient in October and will likely stay elevated as we head into the holiday season.\"\nIf results come is as expected, October would mark a third straight monthly increase in retail sales. However, the rate of growth in consumer spending has slowed considerably in the second half of this year so far, compared to the first half when government stimulus checks and other economic support had helped pad consumers' wallets and stoke spending. The Bureau of Labor Statistics' last report on U.S. GDP showed that personal consumption slowed to a just 1.6% annualized rate in the third quarter, down from a 12.0% clip in the second.\nA jump in prices, as inflationary pressure reverberates across the recovering economy, is one factor economists are closely watching as a potential anchor on consumer spending. While many companies have signaled in their latest earnings reports that they have been able to pass on prices to end users so far, consumers are beginning to take note of rising inflation. Depending on the magnitude and extent of the price increases, this could have a further dampening effect on consumption.\nThe University of Michigan Surveys of Consumers highlighted last week that consumers expected inflation to rise by 4.9% over the next year, which was the highest print since 2008. And the headline index for the University of Michigan showed that the overall sentiment index fell to a 10-year low in early November, in large part reflecting concerns over how inflation would impact consumers' finances. This report came just two days after the Bureau of Labor Statistics' Consumer Price Index (CPI) for October showed that inflation jumped by a greater-than-expected 6.2% compared to the prior year, marking the fastest annual rise since 1990.\n\"It does take a while before a drop in consumer sentiment actually impacts spending,\" Yung-Yu Ma, BMO Wealth Management's chief investment strategist, told Yahoo Finance Live last week.\n\"That's going to be one of the big things going forward, to see whether or not that consumer sentiment can bounce back, whether consumers will be resilient in the face of these price pressures, or whether they'll start to pull back a bit and decide they're going to hold off on spending and wait to see when prices come down or at least stabilize before they spend more in the new year,\" he said. \"So that remains to be seen, and that is a big question mark as we go into 2022.\"\nBig box retailers report earnings\nQuarterly earnings results from companies including Walmart and Target will also be monitored this week as a proxy of consumers' propensity to spend, especially heading into the critical holiday shopping season. The results and earnings calls will also likely include more commentary around how shipping delays and supply chain disruptions are impacting America's largest retailers.\nA back-to-school season that saw many students return to class in-person likely helped stoke spending at both Walmart and Target. Growth still likely slowed compared to earlier on during the pandemic, however, when the companies had benefited from a consumer shift to spending on goods rather than on services, and to big-box stores that would allow them to get all their shopping needs done in one trip during the pandemic.\nWalmart's sales are expected to grow just 1% on a year-over-year basis to reach $135.5 billion, data from Bloomberg showed. This would mark the slowest top-line growth rate since the first quarter of 2020. Total Walmart U.S. same-store sales are expected to grow 7%, however, to accelerate from the prior quarter's 5.4% increase. Walmart U.S. operating margins are also expected to expand to 5.35%, compared to 5.2% in the same quarter last year, but may contract compared to the 6.2% margin posted in the second quarter this year.\nThe logo of Walmart is seen outside of a new Walmart Store in San Salvador, El Salvador, August 21, 2018. REUTERS/Jose CabezasJose Cabezas / Reuters\nAlready last quarter, Walmart executives highlighted during their last earnings call in August that \"out of stocks in certain general merchandise categories\" were \"running above normal given strong sales and supply constraints,\" presaging what many other companies have highlighted in their own earnings results in recent weeks. The firm added at the time that they were also taking steps to try and circumvent supply snarls, including chartering vessels specifically for Walmart goods. All these measures, however, also incur additional costs.\nTarget, for its part, also mentioned it was trying to maneuver around supply chain disruptions on its latest earnings call as well.\n\"Our team has been successfully addressing supply chain bottlenecks, which are affecting both domestic freight and international shipping. Steps include expedited ordering and larger upfront quantities in advance of a season, mitigating the risk that replenishments could take longer than usual,\" said Target Chief Operating Officer John Mulligan in August. \"Bottom line, with Q2 ending inventory up more than 26% or nearly $2.5 billion compared to a year ago, we believe we're well-positioned for the fall and ready to deliver strong growth on top of last year's record increase.\"\nTarget is expected to see revenue grow 8% to $24.09 billion in its fiscal third quarter, also slowing compared to its 9% growth rate in the second quarter and 21% year-over-year increase in the same period last year. Closely watched same-store sales are expected to rise b 8.3%, or slower than the 8.9% rate in the second quarter. Digital same-store sales, however, are anticipated to accelerate sequentially to a 13.25% clip, on top of the 155% digital sales growth Target posted in the same period last year.\nCommentary around labor supply shortages and hiring trends will also be closely watched for both Target and Walmart. In September, Target said it would be hiring 100,000 seasonal employees for the holidays, or fewer than the more than 130,000 workers it hired in each of the last two holiday seasons. It planned to instead provide more hours and pay to its slightly smaller holiday workforce this year.\nWalmart said in September it was planning to hire about 150,000 new U.S. store workers ahead of the holidays, with most of these comprising permanent and full-time roles.\nEconomic calendar\n\nMonday: Empire Manufacturing, Nov. (21.2 expected, 19.8 in prior print)\nTuesday: Retail sales advance, month-over-month, Oct. (1.1% expected, 0.7% in Sept.); Retail sales excluding autos and gas, month-over-month, Oct. (0.9% expected, 0.8% in Sept.); Import price index month-over-month, Oct. (1.0% expected, 0.4% in Sept.); Export price index, month-over-month, Oct. (0.9% expected, 0.1% in Sept.); Industrial Production, month-over-month, Oct. (0.9% expected, -1.3% in Sept.); Capacity Utilization, OCt. (75.9% expected, 75.2% in Sept.); NAHB Housing Market Index, Nov. (80 expected, 80 in Oct.)\nWednesday: MBA mortgage Applications, week ended Nov. 12 (5.5% during prior week); Building permits, month-over-month, Oct. (2.8% expected, -7.8% in Sept.); Housing starts, Oct. (1.6% expected, -1.6% in Sept.)\nThursday: Initial jobless claims, week ended Nov. 13 (260,000 expected, 267,000 during prior week); Continuing claims, week ended Nov. 6 (2.160. million during prior week); Philadelphia Fed Business Outlook, Nov. (24.0 expected, 23.8 in Sept.); Leading Index, Oct. (0.8% expected, 0.2% in Sept.); Kansas City Fed Manufacturing Activity Index, Nov. (31 in Oct.)\nFriday: No notable reports scheduled for release\n\nEarnings calendar\n\nMonday: Oatly (OTLY), WeWork (WE) before market open; Endeavor Group Holdings (EDR), Lucid Group (LCID) after market close\nTuesday: Home Depot (HD), Walmart (WMT) before market open\nWednesday: Lowe's (LOW), Target (TGT), TJX Cos. (TJX) before market open; Sonos (SONO), Nvidia (NVDA), Cisco (CSCO), Victoria's Secret (VSCO) after market close\nThursday: Kohl's (KSS), Macy's (M) before market open; Applied Materials (AMAT), Intuit (INTU), Workday (WDAY), Palo Alto Networks (PANW), Bath & Body Works (BBWI), Williams-Sonoma (WSM) after market close\nFriday: No notable reports scheduled for release","news_type":1},"isVote":1,"tweetType":1,"viewCount":1059,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879767527,"gmtCreate":1636775141114,"gmtModify":1636775141114,"author":{"id":"3581560135544218","authorId":"3581560135544218","name":"xygn","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Buyyyyy","listText":"Buyyyyy","text":"Buyyyyy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/879767527","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p>\n<p>“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p>\n<p>Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p>\n<p>Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p>\n<p>In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p>\n<p>The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p>\n<p>Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).</p>\n<p>The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p>\n<p>The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p>\n<p>The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p>\n<p>While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p>\n<p>In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p>\n<p>The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p>\n<p>“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p>\n<p>Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p>\n<p>“[Pfizer’s] pharmaceutical R&D is better than people had thought.”</p>\n<p>The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p>\n<p>“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p>\n<p>Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).</p>\n<p>“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p>\n<p>Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p>\n<p>“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p>\n<p>That makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p>\n<p>Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p>\n<p>Moderna shares are down more than 40% over the past three months.</p>\n<p>As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p>\n<p>When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p>\n<p>That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p>\n<p>Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p>\n<p>Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p>\n<p>An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-13 11:00 GMT+8 <a href=https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that...</p>\n\n<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1},"isVote":1,"tweetType":1,"viewCount":454,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":851630053,"gmtCreate":1634900589341,"gmtModify":1634900589478,"author":{"id":"3581560135544218","authorId":"3581560135544218","name":"xygn","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/851630053","repostId":"2177914014","repostType":4,"repost":{"id":"2177914014","pubTimestamp":1634894239,"share":"https://www.laohu8.com/m/news/2177914014?lang=&edition=full","pubTime":"2021-10-22 17:17","market":"us","language":"en","title":"5 Stocks To Watch For October 22, 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2177914014","media":"Benzinga","summary":"Some of the stocks that may grab investor focus today are:\n\nWall Street expects Honeywell Internati","content":"<p>Some of the stocks that may grab investor focus today are:</p>\n<ul>\n <li>Wall Street expects <b> Honeywell International Inc </b> (NYSE:HON) to report quarterly earnings at $1.99 per share on revenue of $8.65 billion before the opening bell. Honeywell shares gained 0.4% to $225.50 in after-hours trading.</li>\n <li><b>Intel Corporation</b> (NASDAQ:INTC) reported upbeat earnings for the third quarter, while sales missed estimates. Intel shares, meanwhile, dropped around 9% in after-hours trading on Thursday after the company attributed its computer chip business declining 2% during the third quarter to the ongoing chip shortage. Intel shares dropped 8.8% to $51.10 in the after-hours trading session.</li>\n <li>Analysts are expecting <b> American Express Company </b> (NYSE:AXP) to have earned $1.80 per share on revenue of $10.52 billion for the latest quarter. The company will release earnings before the markets open. American Express shares slipped 0.1% to $177.24 in after-hours trading.</li>\n</ul>\n<ul>\n <li><b>Snap</b> (NYSE:SNAP) reported upbeat earnings for its third quarter, while sales missed expectations. The company also issued Q4 sales guidance below estimates. Snap shares tumbled 21.5% to $59.00 in the after-hours trading session.</li>\n <li>Analysts expect <b> Schlumberger NV </b> (NYSE:SLB) to post quarterly earnings at $0.30 per share on revenue of $5.11 billion before the opening bell. Schlumberger shares fell 0.3% to $34.20 in after-hours trading.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stocks To Watch For October 22, 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stocks To Watch For October 22, 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-22 17:17 GMT+8 <a href=https://www.benzinga.com/news/earnings/21/10/23501927/5-stocks-to-watch-for-october-22-2021><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Some of the stocks that may grab investor focus today are:\n\nWall Street expects Honeywell International Inc (NYSE:HON) to report quarterly earnings at $1.99 per share on revenue of $8.65 billion ...</p>\n\n<a href=\"https://www.benzinga.com/news/earnings/21/10/23501927/5-stocks-to-watch-for-october-22-2021\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNAP":"Snap Inc","AXP":"美国运通","HON":"霍尼韦尔","INTC":"英特尔","SLB":"斯伦贝谢"},"source_url":"https://www.benzinga.com/news/earnings/21/10/23501927/5-stocks-to-watch-for-october-22-2021","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2177914014","content_text":"Some of the stocks that may grab investor focus today are:\n\nWall Street expects Honeywell International Inc (NYSE:HON) to report quarterly earnings at $1.99 per share on revenue of $8.65 billion before the opening bell. Honeywell shares gained 0.4% to $225.50 in after-hours trading.\nIntel Corporation (NASDAQ:INTC) reported upbeat earnings for the third quarter, while sales missed estimates. Intel shares, meanwhile, dropped around 9% in after-hours trading on Thursday after the company attributed its computer chip business declining 2% during the third quarter to the ongoing chip shortage. Intel shares dropped 8.8% to $51.10 in the after-hours trading session.\nAnalysts are expecting American Express Company (NYSE:AXP) to have earned $1.80 per share on revenue of $10.52 billion for the latest quarter. The company will release earnings before the markets open. American Express shares slipped 0.1% to $177.24 in after-hours trading.\n\n\nSnap (NYSE:SNAP) reported upbeat earnings for its third quarter, while sales missed expectations. The company also issued Q4 sales guidance below estimates. Snap shares tumbled 21.5% to $59.00 in the after-hours trading session.\nAnalysts expect Schlumberger NV (NYSE:SLB) to post quarterly earnings at $0.30 per share on revenue of $5.11 billion before the opening bell. Schlumberger shares fell 0.3% to $34.20 in after-hours trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":639,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":878523618,"gmtCreate":1637209023073,"gmtModify":1637209023073,"author":{"id":"3581560135544218","authorId":"3581560135544218","name":"xygn","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Sad","listText":"Sad","text":"Sad","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":15,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/878523618","repostId":"2184510828","repostType":4,"repost":{"id":"2184510828","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1637190577,"share":"https://www.laohu8.com/m/news/2184510828?lang=&edition=full","pubTime":"2021-11-18 07:09","market":"us","language":"en","title":"Wall Street ends lower as retailers stoke inflation fears","url":"https://stock-news.laohu8.com/highlight/detail?id=2184510828","media":"Reuters","summary":" - Wall Street benchmarks ended Wednesday lower on inflation fears and supply chain concerns stemming from retailers' earnings, with investors betting the Federal Reserve will raise interest rates sooner than expected to tame rising prices.$Target Corp$ was the latest big-name retailer to report positive results, upping its annual forecasts and beating profit expectations, citing an early start to holiday shopping.But shares of the firm fell 4.7%, tracking declines in those of peer $Walmart$ on ","content":"<p>(Reuters) - Wall Street benchmarks ended Wednesday lower on inflation fears and supply chain concerns stemming from retailers' earnings, with investors betting the Federal Reserve will raise interest rates sooner than expected to tame rising prices.</p>\n<p><a href=\"https://laohu8.com/S/TG\">Target Corp</a> was the latest big-name retailer to report positive results, upping its annual forecasts and beating profit expectations, citing an early start to holiday shopping.</p>\n<p>But shares of the firm fell 4.7%, tracking declines in those of peer <a href=\"https://laohu8.com/S/WMT\">Walmart</a> on Tuesday, as both retailers flagged a hit to their third-quarter margins from supply chain issues.read more</p>\n<p>Other retailers yet to report earnings traded lower. <a href=\"https://laohu8.com/S/M\">Macy's Inc</a> and Kohls Corp(KSS.N)dropped 4.5% and 3.1% respectively, ahead of posting numbers on Thursday morning, and <a href=\"https://laohu8.com/S/GPS\">Gap Inc</a> and Urban Outfitters Inc(URBN.O), on deck next week, slipped 5.2% and 4.2%.</p>\n<p>Some retailers bucked the trend. TJX Companies Inc(TJX.N)gained 5.8%, its highest finish since Aug. 27, after the T.J. Maxx owner reported estimate-beating earnings, an increase in its share buyback program, and forecast it was well positioned to meet holiday-season demand.read more</p>\n<p>Lowe's Cos Inc(LOW.N)rose 0.4% after the home improvement chain raised its full-year sales forecast on higher demand. Peer Home Depot(HD.N)had also reported strong results on Tuesday.read more</p>\n<p>The Dow was also weighed by <a href=\"https://laohu8.com/S/V\">Visa Inc</a>, which slumped 4.7% after <a href=\"https://laohu8.com/S/AMZN\">Amazon.com Inc</a> said it would stop accepting cards issued by the operator in the UK due to the high transaction fees.read more</p>\n<p>While strong retail data this week showed a rise in inflation has not stifled economic growth so far, investors fear that further increases in prices could hurt growth and push the Federal Reserve into tightening policy ahead of schedule.</p>\n<p>\"You've got inflation at a 31-year high, but we're at the lowest interest rates we've ever had, so those things just don't connect,\" said Salem Abraham, portfolio manager of the Abraham Fortress Fund.</p>\n<p>He added while supply chain issues would ease as COVID moved to endemic status, the huge increase seen in money supply would ensure inflation would remain a serious problem for years.</p>\n<p>Contrasting comments from Fed Presidents James Bullard and Mary Daly on Tuesday also brewed more uncertainty in markets.</p>\n<p>\"The Fed will hold as long as they can ... But if (inflation) continues to go higher, and you continue to see inflationary pressure, then it becomes a question of how many and how often will (rates) rise,\" said Joe Saluzzi, co-manager of trading at Themis Trading in Chatham, New Jersey.</p>\n<p>Strong retail earnings this week will round off an upbeat third-quarter earnings season, which had pushed Wall Street indexes to record highs.</p>\n<p>Chipmaker <a href=\"https://laohu8.com/S/NVDA\">Nvidia Corp</a> dropped 3.1% ahead of its earnings reported after the bell on Wednesday. The wider Philadelphia semiconductor index(.SOX)ended 0.7% lower after a record finish the previous day.</p>\n<p>The Dow Jones Industrial Average(.DJI)fell 211.17 points, or 0.58%, to 35,931.05, the S&P 500(.SPX)lost 12.23 points, or 0.26%, to 4,688.67 and the Nasdaq Composite(.IXIC)dropped 52.28 points, or 0.33%, to 15,921.57.</p>\n<p>Electric vehicle makers were broadly positive. <a href=\"https://laohu8.com/S/TSLA\">Tesla</a> and <a href=\"https://laohu8.com/S/GOEV\">Canoo</a> both gained 3.3%, the latter after forecasting it would start U.S. production sooner than expected. <a href=\"https://laohu8.com/S/SEV\">Sono Group NV</a> surged 155% on its Nasdaq debut.</p>\n<p>But <a href=\"https://laohu8.com/S/RIVN\">Rivian Automotive Inc</a> tumbled 15.1% as investors locked in gains from a near 71% winning streak since the stock's listing last week.</p>\n<p>Volume on U.S. exchanges was 10.6 billion shares, compared with the 11.09 billion average for the full session over the last 20 trading days.</p>\n<p>The S&P 500 posted 41 new 52-week highs and six new lows; the Nasdaq Composite recorded 115 new highs and 244 new lows.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street ends lower as retailers stoke inflation fears</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street ends lower as retailers stoke inflation fears\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-11-18 07:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Reuters) - Wall Street benchmarks ended Wednesday lower on inflation fears and supply chain concerns stemming from retailers' earnings, with investors betting the Federal Reserve will raise interest rates sooner than expected to tame rising prices.</p>\n<p><a href=\"https://laohu8.com/S/TG\">Target Corp</a> was the latest big-name retailer to report positive results, upping its annual forecasts and beating profit expectations, citing an early start to holiday shopping.</p>\n<p>But shares of the firm fell 4.7%, tracking declines in those of peer <a href=\"https://laohu8.com/S/WMT\">Walmart</a> on Tuesday, as both retailers flagged a hit to their third-quarter margins from supply chain issues.read more</p>\n<p>Other retailers yet to report earnings traded lower. <a href=\"https://laohu8.com/S/M\">Macy's Inc</a> and Kohls Corp(KSS.N)dropped 4.5% and 3.1% respectively, ahead of posting numbers on Thursday morning, and <a href=\"https://laohu8.com/S/GPS\">Gap Inc</a> and Urban Outfitters Inc(URBN.O), on deck next week, slipped 5.2% and 4.2%.</p>\n<p>Some retailers bucked the trend. TJX Companies Inc(TJX.N)gained 5.8%, its highest finish since Aug. 27, after the T.J. Maxx owner reported estimate-beating earnings, an increase in its share buyback program, and forecast it was well positioned to meet holiday-season demand.read more</p>\n<p>Lowe's Cos Inc(LOW.N)rose 0.4% after the home improvement chain raised its full-year sales forecast on higher demand. Peer Home Depot(HD.N)had also reported strong results on Tuesday.read more</p>\n<p>The Dow was also weighed by <a href=\"https://laohu8.com/S/V\">Visa Inc</a>, which slumped 4.7% after <a href=\"https://laohu8.com/S/AMZN\">Amazon.com Inc</a> said it would stop accepting cards issued by the operator in the UK due to the high transaction fees.read more</p>\n<p>While strong retail data this week showed a rise in inflation has not stifled economic growth so far, investors fear that further increases in prices could hurt growth and push the Federal Reserve into tightening policy ahead of schedule.</p>\n<p>\"You've got inflation at a 31-year high, but we're at the lowest interest rates we've ever had, so those things just don't connect,\" said Salem Abraham, portfolio manager of the Abraham Fortress Fund.</p>\n<p>He added while supply chain issues would ease as COVID moved to endemic status, the huge increase seen in money supply would ensure inflation would remain a serious problem for years.</p>\n<p>Contrasting comments from Fed Presidents James Bullard and Mary Daly on Tuesday also brewed more uncertainty in markets.</p>\n<p>\"The Fed will hold as long as they can ... But if (inflation) continues to go higher, and you continue to see inflationary pressure, then it becomes a question of how many and how often will (rates) rise,\" said Joe Saluzzi, co-manager of trading at Themis Trading in Chatham, New Jersey.</p>\n<p>Strong retail earnings this week will round off an upbeat third-quarter earnings season, which had pushed Wall Street indexes to record highs.</p>\n<p>Chipmaker <a href=\"https://laohu8.com/S/NVDA\">Nvidia Corp</a> dropped 3.1% ahead of its earnings reported after the bell on Wednesday. The wider Philadelphia semiconductor index(.SOX)ended 0.7% lower after a record finish the previous day.</p>\n<p>The Dow Jones Industrial Average(.DJI)fell 211.17 points, or 0.58%, to 35,931.05, the S&P 500(.SPX)lost 12.23 points, or 0.26%, to 4,688.67 and the Nasdaq Composite(.IXIC)dropped 52.28 points, or 0.33%, to 15,921.57.</p>\n<p>Electric vehicle makers were broadly positive. <a href=\"https://laohu8.com/S/TSLA\">Tesla</a> and <a href=\"https://laohu8.com/S/GOEV\">Canoo</a> both gained 3.3%, the latter after forecasting it would start U.S. production sooner than expected. <a href=\"https://laohu8.com/S/SEV\">Sono Group NV</a> surged 155% on its Nasdaq debut.</p>\n<p>But <a href=\"https://laohu8.com/S/RIVN\">Rivian Automotive Inc</a> tumbled 15.1% as investors locked in gains from a near 71% winning streak since the stock's listing last week.</p>\n<p>Volume on U.S. exchanges was 10.6 billion shares, compared with the 11.09 billion average for the full session over the last 20 trading days.</p>\n<p>The S&P 500 posted 41 new 52-week highs and six new lows; the Nasdaq Composite recorded 115 new highs and 244 new lows.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index","APR":"Apria, Inc.","QID":"纳指两倍做空ETF",".IXIC":"NASDAQ Composite","CGEM":"Cullinan Therapeutics","LABP":"Landos Biopharma, Inc.",".DJI":"道琼斯","DDM":"道指两倍做多ETF","LHDX":"Lucira Health, Inc.","DJX":"1/100道琼斯","UDOW":"道指三倍做多ETF-ProShares","DXD":"道指两倍做空ETF","QLD":"纳指两倍做多ETF","PSQ":"纳指反向ETF","DOG":"道指反向ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2184510828","content_text":"(Reuters) - Wall Street benchmarks ended Wednesday lower on inflation fears and supply chain concerns stemming from retailers' earnings, with investors betting the Federal Reserve will raise interest rates sooner than expected to tame rising prices.\nTarget Corp was the latest big-name retailer to report positive results, upping its annual forecasts and beating profit expectations, citing an early start to holiday shopping.\nBut shares of the firm fell 4.7%, tracking declines in those of peer Walmart on Tuesday, as both retailers flagged a hit to their third-quarter margins from supply chain issues.read more\nOther retailers yet to report earnings traded lower. Macy's Inc and Kohls Corp(KSS.N)dropped 4.5% and 3.1% respectively, ahead of posting numbers on Thursday morning, and Gap Inc and Urban Outfitters Inc(URBN.O), on deck next week, slipped 5.2% and 4.2%.\nSome retailers bucked the trend. TJX Companies Inc(TJX.N)gained 5.8%, its highest finish since Aug. 27, after the T.J. Maxx owner reported estimate-beating earnings, an increase in its share buyback program, and forecast it was well positioned to meet holiday-season demand.read more\nLowe's Cos Inc(LOW.N)rose 0.4% after the home improvement chain raised its full-year sales forecast on higher demand. Peer Home Depot(HD.N)had also reported strong results on Tuesday.read more\nThe Dow was also weighed by Visa Inc, which slumped 4.7% after Amazon.com Inc said it would stop accepting cards issued by the operator in the UK due to the high transaction fees.read more\nWhile strong retail data this week showed a rise in inflation has not stifled economic growth so far, investors fear that further increases in prices could hurt growth and push the Federal Reserve into tightening policy ahead of schedule.\n\"You've got inflation at a 31-year high, but we're at the lowest interest rates we've ever had, so those things just don't connect,\" said Salem Abraham, portfolio manager of the Abraham Fortress Fund.\nHe added while supply chain issues would ease as COVID moved to endemic status, the huge increase seen in money supply would ensure inflation would remain a serious problem for years.\nContrasting comments from Fed Presidents James Bullard and Mary Daly on Tuesday also brewed more uncertainty in markets.\n\"The Fed will hold as long as they can ... But if (inflation) continues to go higher, and you continue to see inflationary pressure, then it becomes a question of how many and how often will (rates) rise,\" said Joe Saluzzi, co-manager of trading at Themis Trading in Chatham, New Jersey.\nStrong retail earnings this week will round off an upbeat third-quarter earnings season, which had pushed Wall Street indexes to record highs.\nChipmaker Nvidia Corp dropped 3.1% ahead of its earnings reported after the bell on Wednesday. The wider Philadelphia semiconductor index(.SOX)ended 0.7% lower after a record finish the previous day.\nThe Dow Jones Industrial Average(.DJI)fell 211.17 points, or 0.58%, to 35,931.05, the S&P 500(.SPX)lost 12.23 points, or 0.26%, to 4,688.67 and the Nasdaq Composite(.IXIC)dropped 52.28 points, or 0.33%, to 15,921.57.\nElectric vehicle makers were broadly positive. Tesla and Canoo both gained 3.3%, the latter after forecasting it would start U.S. production sooner than expected. Sono Group NV surged 155% on its Nasdaq debut.\nBut Rivian Automotive Inc tumbled 15.1% as investors locked in gains from a near 71% winning streak since the stock's listing last week.\nVolume on U.S. exchanges was 10.6 billion shares, compared with the 11.09 billion average for the full session over the last 20 trading days.\nThe S&P 500 posted 41 new 52-week highs and six new lows; the Nasdaq Composite recorded 115 new highs and 244 new lows.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1375,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3582839637303229","authorId":"3582839637303229","name":"vxf","avatar":"https://static.tigerbbs.com/b1ee9a28e0a19bf5b87d52e90dc87788","crmLevel":2,"crmLevelSwitch":0},"content":"大家好, 请随时查看我关于数字货币之旅的个人资料。 它只用于分享,简单的PDF,没有骗局。感谢&安培;祝你有愉快的一天。","text":"大家好, 请随时查看我关于数字货币之旅的个人资料。 它只用于分享,简单的PDF,没有骗局。感谢&安培;祝你有愉快的一天。","html":"大家好, 请随时查看我关于数字货币之旅的个人资料。 它只用于分享,简单的PDF,没有骗局。感谢&安培;祝你有愉快的一天。"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879767527,"gmtCreate":1636775141114,"gmtModify":1636775141114,"author":{"id":"3581560135544218","authorId":"3581560135544218","name":"xygn","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Buyyyyy","listText":"Buyyyyy","text":"Buyyyyy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/879767527","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p>\n<p>“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p>\n<p>Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p>\n<p>Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p>\n<p>In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p>\n<p>The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p>\n<p>Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).</p>\n<p>The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p>\n<p>The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p>\n<p>The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p>\n<p>While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p>\n<p>In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p>\n<p>The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p>\n<p>“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p>\n<p>Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p>\n<p>“[Pfizer’s] pharmaceutical R&D is better than people had thought.”</p>\n<p>The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p>\n<p>“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p>\n<p>Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).</p>\n<p>“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p>\n<p>Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p>\n<p>“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p>\n<p>That makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p>\n<p>Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p>\n<p>Moderna shares are down more than 40% over the past three months.</p>\n<p>As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p>\n<p>When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p>\n<p>That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p>\n<p>Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p>\n<p>Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p>\n<p>An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-13 11:00 GMT+8 <a href=https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that...</p>\n\n<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1},"isVote":1,"tweetType":1,"viewCount":454,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873595369,"gmtCreate":1636957479818,"gmtModify":1636957486626,"author":{"id":"3581560135544218","authorId":"3581560135544218","name":"xygn","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873595369","repostId":"2183536049","repostType":4,"repost":{"id":"2183536049","pubTimestamp":1636931077,"share":"https://www.laohu8.com/m/news/2183536049?lang=&edition=full","pubTime":"2021-11-15 07:04","market":"us","language":"en","title":"Retail sales, Walmart and Target earnings: What to know this week","url":"https://stock-news.laohu8.com/highlight/detail?id=2183536049","media":"Yahoo Finance","summary":"Investors this week will be focused on data on the consumer, with both retail sales and earnings results from two retail giants set for release.The total value of retail sales in the U.S. is expected to have climbed by 1.1% month-on-month in October, according to the Commerce Department's latest monthly print on Tuesday. This would accelerate from a 0.7% monthly advance in September, which had been an unexpected increase at the time given that many economists were anticipating that a rise in Del","content":"<p><img src=\"https://static.tigerbbs.com/08676f0472643b38e9d755d70877271b\" tg-width=\"1878\" tg-height=\"2390\" referrerpolicy=\"no-referrer\"></p>\n<p>Investors this week will be focused on data on the consumer, with both retail sales and earnings results from two retail giants set for release.</p>\n<p>The total value of retail sales in the U.S. is expected to have climbed by 1.1% month-on-month in October, according to the Commerce Department's latest monthly print on Tuesday. This would accelerate from a 0.7% monthly advance in September, which had been an unexpected increase at the time given that many economists were anticipating that a rise in Delta variant cases would weigh on spending during the month.</p>\n<p>\"Our data suggest broad-based improvement across major sectors, including restaurants, department stores and general merchandise,\" Bank of America economist Michelle Meyer wrote in a note on Friday. \"Netting out restaurants, gas and building materials, we look for the core control group to increase 0.5% [month-over-month]. Consumer spending remained resilient in October and will likely stay elevated as we head into the holiday season.\"</p>\n<p>If results come is as expected, October would mark a third straight monthly increase in retail sales. However, the rate of growth in consumer spending has slowed considerably in the second half of this year so far, compared to the first half when government stimulus checks and other economic support had helped pad consumers' wallets and stoke spending. The Bureau of Labor Statistics' last report on U.S. GDP showed that personal consumption slowed to a just 1.6% annualized rate in the third quarter, down from a 12.0% clip in the second.</p>\n<p>A jump in prices, as inflationary pressure reverberates across the recovering economy, is <a href=\"https://laohu8.com/S/AONE.U\">one</a> factor economists are closely watching as a potential anchor on consumer spending. While many companies have signaled in their latest earnings reports that they have been able to pass on prices to end users so far, consumers are beginning to take note of rising inflation. Depending on the magnitude and extent of the price increases, this could have a further dampening effect on consumption.</p>\n<p>The University of Michigan Surveys of Consumers highlighted last week that consumers expected inflation to rise by 4.9% over the next year, which was the highest print since 2008. And the headline index for the University of Michigan showed that the overall sentiment index fell to a 10-year low in early November, in large part reflecting concerns over how inflation would impact consumers' finances. This report came just two days after the Bureau of Labor Statistics' Consumer Price Index (CPI) for October showed that inflation jumped by a greater-than-expected 6.2% compared to the prior year, marking the fastest annual rise since 1990.</p>\n<p>\"It does take a while before a drop in consumer sentiment actually impacts spending,\" Yung-Yu Ma, BMO Wealth Management's chief investment strategist, told Yahoo Finance Live last week.</p>\n<p>\"That's going to be one of the big things going forward, to see whether or not that consumer sentiment can bounce back, whether consumers will be resilient in the face of these price pressures, or whether they'll start to pull back a bit and decide they're going to hold off on spending and wait to see when prices come down or at least stabilize before they spend more in the new year,\" he said. \"So that remains to be seen, and that is a big question mark as we go into 2022.\"</p>\n<h2>Big box retailers report earnings</h2>\n<p>Quarterly earnings results from companies including Walmart and Target will also be monitored this week as a proxy of consumers' propensity to spend, especially heading into the critical holiday shopping season. The results and earnings calls will also likely include more commentary around how shipping delays and supply chain disruptions are impacting America's largest retailers.</p>\n<p>A back-to-school season that saw many students return to class in-person likely helped stoke spending at both Walmart and Target. Growth still likely slowed compared to earlier on during the pandemic, however, when the companies had benefited from a consumer shift to spending on goods rather than on services, and to big-box stores that would allow them to get all their shopping needs done in one trip during the pandemic.</p>\n<p>Walmart's sales are expected to grow just 1% on a year-over-year basis to reach $135.5 billion, data from Bloomberg showed. This would mark the slowest top-line growth rate since the first quarter of 2020. Total Walmart U.S. same-store sales are expected to grow 7%, however, to accelerate from the prior quarter's 5.4% increase. Walmart U.S. operating margins are also expected to expand to 5.35%, compared to 5.2% in the same quarter last year, but may contract compared to the 6.2% margin posted in the second quarter this year.</p>\n<p><img src=\"https://static.tigerbbs.com/cc803a27e7a5de4f45494c90d84e6e2c\" tg-width=\"6720\" tg-height=\"4480\" referrerpolicy=\"no-referrer\">The logo of Walmart is seen outside of a new Walmart Store in San Salvador, El Salvador, August 21, 2018. REUTERS/Jose CabezasJose Cabezas / Reuters</p>\n<p>Already last quarter, Walmart executives highlighted during their last earnings call in August that \"out of stocks in certain general merchandise categories\" were \"running above normal given strong sales and supply constraints,\" presaging what many other companies have highlighted in their own earnings results in recent weeks. The firm added at the time that they were also taking steps to try and circumvent supply snarls, including chartering vessels specifically for Walmart goods. All these measures, however, also incur additional costs.</p>\n<p>Target, for its part, also mentioned it was trying to maneuver around supply chain disruptions on its latest earnings call as well.</p>\n<p>\"Our team has been successfully addressing supply chain bottlenecks, which are affecting both domestic freight and international shipping. Steps include expedited ordering and larger upfront quantities in advance of a season, mitigating the risk that replenishments could take longer than usual,\" said Target Chief Operating Officer John Mulligan in August. \"Bottom line, with Q2 ending inventory up more than 26% or nearly $2.5 billion compared to a year ago, we believe we're well-positioned for the fall and ready to deliver strong growth on top of last year's record increase.\"</p>\n<p>Target is expected to see revenue grow 8% to $24.09 billion in its fiscal third quarter, also slowing compared to its 9% growth rate in the second quarter and 21% year-over-year increase in the same period last year. Closely watched same-store sales are expected to rise b 8.3%, or slower than the 8.9% rate in the second quarter. Digital same-store sales, however, are anticipated to accelerate sequentially to a 13.25% clip, on top of the 155% digital sales growth Target posted in the same period last year.</p>\n<p>Commentary around labor supply shortages and hiring trends will also be closely watched for both Target and Walmart. In September, Target said it would be hiring 100,000 seasonal employees for the holidays, or fewer than the more than 130,000 workers it hired in each of the last two holiday seasons. It planned to instead provide more hours and pay to its slightly smaller holiday workforce this year.</p>\n<p>Walmart said in September it was planning to hire about 150,000 new U.S. store workers ahead of the holidays, with most of these comprising permanent and full-time roles.</p>\n<h2>Economic calendar</h2>\n<ul>\n <li><p><b>Monday: </b>Empire Manufacturing, Nov. (21.2 expected, 19.8 in prior print)</p></li>\n <li><p><b>Tuesday: </b>Retail sales advance, month-over-month, Oct. (1.1% expected, 0.7% in Sept.); Retail sales excluding autos and gas, month-over-month, Oct. (0.9% expected, 0.8% in Sept.); Import price index month-over-month, Oct. (1.0% expected, 0.4% in Sept.); Export price index, month-over-month, Oct. (0.9% expected, 0.1% in Sept.); Industrial Production, month-over-month, Oct. (0.9% expected, -1.3% in Sept.); Capacity Utilization, OCt. (75.9% expected, 75.2% in Sept.); NAHB Housing Market Index, Nov. (80 expected, 80 in Oct.)</p></li>\n <li><p><b>Wednesday: </b>MBA mortgage Applications, week ended Nov. 12 (5.5% during prior week); Building permits, month-over-month, Oct. (2.8% expected, -7.8% in Sept.); Housing starts, Oct. (1.6% expected, -1.6% in Sept.)</p></li>\n <li><p><b>Thursday: </b>Initial jobless claims, week ended Nov. 13 (260,000 expected, 267,000 during prior week); Continuing claims, week ended Nov. 6 (2.160. million during prior week); Philadelphia Fed Business Outlook, Nov. (24.0 expected, 23.8 in Sept.); Leading Index, Oct. (0.8% expected, 0.2% in Sept.); Kansas City Fed Manufacturing Activity Index, Nov. (31 in Oct.)</p></li>\n <li><p><b>Friday: </b><i>No notable reports scheduled for release</i></p></li>\n</ul>\n<h2>Earnings calendar</h2>\n<ul>\n <li><p><b>Monday:</b> Oatly (OTLY), <a href=\"https://laohu8.com/S/WE\">WeWork</a> (WE) before market open; Endeavor Group Holdings (EDR), Lucid Group (LCID) after market close</p></li>\n <li><p><b>Tuesday: </b>Home Depot (HD), Walmart (WMT) before market open</p></li>\n <li><p><b>Wednesday: </b>Lowe's (LOW), Target (TGT), TJX Cos. (TJX) before market open; Sonos (SONO), Nvidia (NVDA), Cisco (CSCO), Victoria's Secret (VSCO) after market close</p></li>\n <li><p><b>Thursday: </b>Kohl's (KSS), Macy's (M) before market open; Applied Materials (AMAT), Intuit (INTU), <a href=\"https://laohu8.com/S/WDAY\">Workday</a> (WDAY), <a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a> (PANW), Bath & Body Works (BBWI), Williams-Sonoma (WSM) after market close</p></li>\n <li><p><b>Friday: </b><i>No notable reports scheduled for release</i></p></li>\n</ul>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Retail sales, Walmart and Target earnings: What to know this week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRetail sales, Walmart and Target earnings: What to know this week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-15 07:04 GMT+8 <a href=https://finance.yahoo.com/news/retail-sales-and-retailers-earnings-what-to-know-this-week-154433076.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors this week will be focused on data on the consumer, with both retail sales and earnings results from two retail giants set for release.\nThe total value of retail sales in the U.S. is expected...</p>\n\n<a href=\"https://finance.yahoo.com/news/retail-sales-and-retailers-earnings-what-to-know-this-week-154433076.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite","TGT":"塔吉特","WMT":"沃尔玛"},"source_url":"https://finance.yahoo.com/news/retail-sales-and-retailers-earnings-what-to-know-this-week-154433076.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2183536049","content_text":"Investors this week will be focused on data on the consumer, with both retail sales and earnings results from two retail giants set for release.\nThe total value of retail sales in the U.S. is expected to have climbed by 1.1% month-on-month in October, according to the Commerce Department's latest monthly print on Tuesday. This would accelerate from a 0.7% monthly advance in September, which had been an unexpected increase at the time given that many economists were anticipating that a rise in Delta variant cases would weigh on spending during the month.\n\"Our data suggest broad-based improvement across major sectors, including restaurants, department stores and general merchandise,\" Bank of America economist Michelle Meyer wrote in a note on Friday. \"Netting out restaurants, gas and building materials, we look for the core control group to increase 0.5% [month-over-month]. Consumer spending remained resilient in October and will likely stay elevated as we head into the holiday season.\"\nIf results come is as expected, October would mark a third straight monthly increase in retail sales. However, the rate of growth in consumer spending has slowed considerably in the second half of this year so far, compared to the first half when government stimulus checks and other economic support had helped pad consumers' wallets and stoke spending. The Bureau of Labor Statistics' last report on U.S. GDP showed that personal consumption slowed to a just 1.6% annualized rate in the third quarter, down from a 12.0% clip in the second.\nA jump in prices, as inflationary pressure reverberates across the recovering economy, is one factor economists are closely watching as a potential anchor on consumer spending. While many companies have signaled in their latest earnings reports that they have been able to pass on prices to end users so far, consumers are beginning to take note of rising inflation. Depending on the magnitude and extent of the price increases, this could have a further dampening effect on consumption.\nThe University of Michigan Surveys of Consumers highlighted last week that consumers expected inflation to rise by 4.9% over the next year, which was the highest print since 2008. And the headline index for the University of Michigan showed that the overall sentiment index fell to a 10-year low in early November, in large part reflecting concerns over how inflation would impact consumers' finances. This report came just two days after the Bureau of Labor Statistics' Consumer Price Index (CPI) for October showed that inflation jumped by a greater-than-expected 6.2% compared to the prior year, marking the fastest annual rise since 1990.\n\"It does take a while before a drop in consumer sentiment actually impacts spending,\" Yung-Yu Ma, BMO Wealth Management's chief investment strategist, told Yahoo Finance Live last week.\n\"That's going to be one of the big things going forward, to see whether or not that consumer sentiment can bounce back, whether consumers will be resilient in the face of these price pressures, or whether they'll start to pull back a bit and decide they're going to hold off on spending and wait to see when prices come down or at least stabilize before they spend more in the new year,\" he said. \"So that remains to be seen, and that is a big question mark as we go into 2022.\"\nBig box retailers report earnings\nQuarterly earnings results from companies including Walmart and Target will also be monitored this week as a proxy of consumers' propensity to spend, especially heading into the critical holiday shopping season. The results and earnings calls will also likely include more commentary around how shipping delays and supply chain disruptions are impacting America's largest retailers.\nA back-to-school season that saw many students return to class in-person likely helped stoke spending at both Walmart and Target. Growth still likely slowed compared to earlier on during the pandemic, however, when the companies had benefited from a consumer shift to spending on goods rather than on services, and to big-box stores that would allow them to get all their shopping needs done in one trip during the pandemic.\nWalmart's sales are expected to grow just 1% on a year-over-year basis to reach $135.5 billion, data from Bloomberg showed. This would mark the slowest top-line growth rate since the first quarter of 2020. Total Walmart U.S. same-store sales are expected to grow 7%, however, to accelerate from the prior quarter's 5.4% increase. Walmart U.S. operating margins are also expected to expand to 5.35%, compared to 5.2% in the same quarter last year, but may contract compared to the 6.2% margin posted in the second quarter this year.\nThe logo of Walmart is seen outside of a new Walmart Store in San Salvador, El Salvador, August 21, 2018. REUTERS/Jose CabezasJose Cabezas / Reuters\nAlready last quarter, Walmart executives highlighted during their last earnings call in August that \"out of stocks in certain general merchandise categories\" were \"running above normal given strong sales and supply constraints,\" presaging what many other companies have highlighted in their own earnings results in recent weeks. The firm added at the time that they were also taking steps to try and circumvent supply snarls, including chartering vessels specifically for Walmart goods. All these measures, however, also incur additional costs.\nTarget, for its part, also mentioned it was trying to maneuver around supply chain disruptions on its latest earnings call as well.\n\"Our team has been successfully addressing supply chain bottlenecks, which are affecting both domestic freight and international shipping. Steps include expedited ordering and larger upfront quantities in advance of a season, mitigating the risk that replenishments could take longer than usual,\" said Target Chief Operating Officer John Mulligan in August. \"Bottom line, with Q2 ending inventory up more than 26% or nearly $2.5 billion compared to a year ago, we believe we're well-positioned for the fall and ready to deliver strong growth on top of last year's record increase.\"\nTarget is expected to see revenue grow 8% to $24.09 billion in its fiscal third quarter, also slowing compared to its 9% growth rate in the second quarter and 21% year-over-year increase in the same period last year. Closely watched same-store sales are expected to rise b 8.3%, or slower than the 8.9% rate in the second quarter. Digital same-store sales, however, are anticipated to accelerate sequentially to a 13.25% clip, on top of the 155% digital sales growth Target posted in the same period last year.\nCommentary around labor supply shortages and hiring trends will also be closely watched for both Target and Walmart. In September, Target said it would be hiring 100,000 seasonal employees for the holidays, or fewer than the more than 130,000 workers it hired in each of the last two holiday seasons. It planned to instead provide more hours and pay to its slightly smaller holiday workforce this year.\nWalmart said in September it was planning to hire about 150,000 new U.S. store workers ahead of the holidays, with most of these comprising permanent and full-time roles.\nEconomic calendar\n\nMonday: Empire Manufacturing, Nov. (21.2 expected, 19.8 in prior print)\nTuesday: Retail sales advance, month-over-month, Oct. (1.1% expected, 0.7% in Sept.); Retail sales excluding autos and gas, month-over-month, Oct. (0.9% expected, 0.8% in Sept.); Import price index month-over-month, Oct. (1.0% expected, 0.4% in Sept.); Export price index, month-over-month, Oct. (0.9% expected, 0.1% in Sept.); Industrial Production, month-over-month, Oct. (0.9% expected, -1.3% in Sept.); Capacity Utilization, OCt. (75.9% expected, 75.2% in Sept.); NAHB Housing Market Index, Nov. (80 expected, 80 in Oct.)\nWednesday: MBA mortgage Applications, week ended Nov. 12 (5.5% during prior week); Building permits, month-over-month, Oct. (2.8% expected, -7.8% in Sept.); Housing starts, Oct. (1.6% expected, -1.6% in Sept.)\nThursday: Initial jobless claims, week ended Nov. 13 (260,000 expected, 267,000 during prior week); Continuing claims, week ended Nov. 6 (2.160. million during prior week); Philadelphia Fed Business Outlook, Nov. (24.0 expected, 23.8 in Sept.); Leading Index, Oct. (0.8% expected, 0.2% in Sept.); Kansas City Fed Manufacturing Activity Index, Nov. (31 in Oct.)\nFriday: No notable reports scheduled for release\n\nEarnings calendar\n\nMonday: Oatly (OTLY), WeWork (WE) before market open; Endeavor Group Holdings (EDR), Lucid Group (LCID) after market close\nTuesday: Home Depot (HD), Walmart (WMT) before market open\nWednesday: Lowe's (LOW), Target (TGT), TJX Cos. (TJX) before market open; Sonos (SONO), Nvidia (NVDA), Cisco (CSCO), Victoria's Secret (VSCO) after market close\nThursday: Kohl's (KSS), Macy's (M) before market open; Applied Materials (AMAT), Intuit (INTU), Workday (WDAY), Palo Alto Networks (PANW), Bath & Body Works (BBWI), Williams-Sonoma (WSM) after market close\nFriday: No notable reports scheduled for release","news_type":1},"isVote":1,"tweetType":1,"viewCount":1059,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":851630053,"gmtCreate":1634900589341,"gmtModify":1634900589478,"author":{"id":"3581560135544218","authorId":"3581560135544218","name":"xygn","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/851630053","repostId":"2177914014","repostType":4,"isVote":1,"tweetType":1,"viewCount":639,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691432647,"gmtCreate":1640226400337,"gmtModify":1640226400421,"author":{"id":"3581560135544218","authorId":"3581560135544218","name":"xygn","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691432647","repostId":"1119859400","repostType":4,"repost":{"id":"1119859400","pubTimestamp":1640226140,"share":"https://www.laohu8.com/m/news/1119859400?lang=&edition=full","pubTime":"2021-12-23 10:22","market":"us","language":"en","title":"Rivian vs. Ford: Which Is the Better Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=1119859400","media":"InvestorPlace","summary":"Rivian has great potential, but is it a better buy than something like Ford?","content":"<p><b>Rivian</b>(NASDAQ:<b><u>RIVN</u></b>) recently hit new lows on Dec. 17 after reporting earnings. RIVN stock fell 10% as a result of a top- and bottom-line miss, the company’s first report as a public company.</p>\n<p>Even with the drop, Rivian commands a market capitalization of $84 billion. That’s more than <b>Ford</b>(NYSE:<b><u>F</u></b>) and <b>General Motors</b>(NYSE:<b><u>GM</u></b>). That’s crazy!</p>\n<p>The valuation with electric vehicle (EV) stocks has gone bananas.</p>\n<p>In the pre-EV days, automakers were assigned insultingly low valuations. Perhaps we’re in the midst of a great “rerating” in terms of valuation, but building EVs vs. traditional internal combustion engine (ICE) vehicles<i>shouldn’t</i>create such disparity with the valuation.</p>\n<p>That’s where we find ourselves though, as investors wonder if this shift is permanent or temporary.</p>\n<p>I don’t have anything personal against RIVN stock, but I personally find its valuation to be too high. Shares trade at about 10.4 times 2023 estimates, estimates of which may very well may be too optimistic in the first place.</p>\n<p>That’s got me comparing it to other automakers, namely Ford.</p>\n<p><b>RIVN Stock vs. F Stock</b></p>\n<p>Rivian does not generate meaningful revenue at the moment, although it does have a partnership with <b>Amazon</b>(NASDAQ:<b><u>AMZN</u></b>). The latter also owns a 20% stake in the company, for what it’s worth.</p>\n<p>Estimates currently call for $3.45 billion in sales next year for Rivian, although that estimate is at risk (in my opinion) as management has said supply chain issues could negatively impact deliveries. On the plus side, there are 71,000 RI reservations for its new vehicle.That’s up 48% in the last two and a half months.</p>\n<p>But then you flip around to Ford and ask yourself, “If Rivian is worth $84 billion, why is Ford only worth $80 billion?”</p>\n<p>The company is forecast to generate ~$127 billion in sales in 2021, up 9.5% year over year. In 2022 and 2023, estimates sit at $145.3 billion and $164 billion, respectively.</p>\n<p>The latter figure is almost 20 times larger than the $8.4 billion Rivian is forecast to generate that year. Now that comparison is a bit like apples to oranges, but it highlights the difference between these two companies and what stage they are at.</p>\n<p>Rivian is like the kid that walked into the office and was promoted to VP on their first day. Ford has been there for 30 years and still can’t make partner.</p>\n<p><b>Truck vs. Truck</b></p>\n<p>Ford is making a serious transition toward EVs. It already has its Mustang Mach E on the road, with the E-Transit on the way. Ford even has a pilot program to help companies integrate the E-Transit into their fleets.</p>\n<p>But the crown jewel is the F-150 Lightning.</p>\n<p>The F-Series pickup truck is the best selling<i>vehicle</i>in the U.S. and has been for more than four decades. While Rivian has an impressive 71,000 reservations, Ford stopped taking reservations for its F-150 Lightning, as the list topped 200,000.</p>\n<p>Demand is clearly through the roof here. While that has many investors optimistic on the future of EV and specifically on Rivian, why don’t they see the competition that’s coming down the pike?</p>\n<p>It would be one thing if Rivian was going to enter the electric pickup truck market with no competition. But the fact that it’s fighting the electrification of the country’s best-selling pickup and vehicle,andgoing up against<b>Tesla</b>(NASDAQ:<b><u>TSLA</u></b>), GM and others, should have investors asking some questions.</p>\n<p>Namely this: Is RIVN stock overvalued or is F stock undervalued — or is it both?</p>\n<p>Granted, the R1T has a better EPA-estimated driving range for its base model than the base model for Ford’s Lightning. That said, Ford’s electric pickup starts at around $40,000 and can get an upgrade to its range, while the R1T has a starting price of roughly $67,500.</p>\n<p>Ford expects to “increase its production capacity of electric vehicles to 600,000 units globally by 2023.” Further, CEO Jim Farley “expects that would make the company the second-largest U.S.-based producer of EVs,” just behind <b>Tesla</b>(NASDAQ:<b><u>TSLA</u></b>).</p>\n<p>For what it’s worth, General Motors will likely be in that mix as well, with management previously stating it expects to produce 1 million EVs by 2025.</p>\n<p><b>Bottom Line on RIVN Stock</b></p>\n<p>I must repeat again that I don’t have anything personal against Rivian. I actually really like EVs and autonomous driving systems and I covered the space for years.</p>\n<p>But the sudden fascination with this industry — shown via the valuations — has me asking some questions as to how it’s justified. For now, I still don’t have the answer and, between the two stocks, I’d rather be long Ford at these levels than RIVN stock.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rivian vs. Ford: Which Is the Better Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRivian vs. Ford: Which Is the Better Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 10:22 GMT+8 <a href=https://investorplace.com/2021/12/rivian-rivn-stock-vs-ford-which-is-the-better-buy/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Rivian(NASDAQ:RIVN) recently hit new lows on Dec. 17 after reporting earnings. RIVN stock fell 10% as a result of a top- and bottom-line miss, the company’s first report as a public company.\nEven with...</p>\n\n<a href=\"https://investorplace.com/2021/12/rivian-rivn-stock-vs-ford-which-is-the-better-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"F":"福特汽车","RIVN":"Rivian Automotive, Inc."},"source_url":"https://investorplace.com/2021/12/rivian-rivn-stock-vs-ford-which-is-the-better-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1119859400","content_text":"Rivian(NASDAQ:RIVN) recently hit new lows on Dec. 17 after reporting earnings. RIVN stock fell 10% as a result of a top- and bottom-line miss, the company’s first report as a public company.\nEven with the drop, Rivian commands a market capitalization of $84 billion. That’s more than Ford(NYSE:F) and General Motors(NYSE:GM). That’s crazy!\nThe valuation with electric vehicle (EV) stocks has gone bananas.\nIn the pre-EV days, automakers were assigned insultingly low valuations. Perhaps we’re in the midst of a great “rerating” in terms of valuation, but building EVs vs. traditional internal combustion engine (ICE) vehiclesshouldn’tcreate such disparity with the valuation.\nThat’s where we find ourselves though, as investors wonder if this shift is permanent or temporary.\nI don’t have anything personal against RIVN stock, but I personally find its valuation to be too high. Shares trade at about 10.4 times 2023 estimates, estimates of which may very well may be too optimistic in the first place.\nThat’s got me comparing it to other automakers, namely Ford.\nRIVN Stock vs. F Stock\nRivian does not generate meaningful revenue at the moment, although it does have a partnership with Amazon(NASDAQ:AMZN). The latter also owns a 20% stake in the company, for what it’s worth.\nEstimates currently call for $3.45 billion in sales next year for Rivian, although that estimate is at risk (in my opinion) as management has said supply chain issues could negatively impact deliveries. On the plus side, there are 71,000 RI reservations for its new vehicle.That’s up 48% in the last two and a half months.\nBut then you flip around to Ford and ask yourself, “If Rivian is worth $84 billion, why is Ford only worth $80 billion?”\nThe company is forecast to generate ~$127 billion in sales in 2021, up 9.5% year over year. In 2022 and 2023, estimates sit at $145.3 billion and $164 billion, respectively.\nThe latter figure is almost 20 times larger than the $8.4 billion Rivian is forecast to generate that year. Now that comparison is a bit like apples to oranges, but it highlights the difference between these two companies and what stage they are at.\nRivian is like the kid that walked into the office and was promoted to VP on their first day. Ford has been there for 30 years and still can’t make partner.\nTruck vs. Truck\nFord is making a serious transition toward EVs. It already has its Mustang Mach E on the road, with the E-Transit on the way. Ford even has a pilot program to help companies integrate the E-Transit into their fleets.\nBut the crown jewel is the F-150 Lightning.\nThe F-Series pickup truck is the best sellingvehiclein the U.S. and has been for more than four decades. While Rivian has an impressive 71,000 reservations, Ford stopped taking reservations for its F-150 Lightning, as the list topped 200,000.\nDemand is clearly through the roof here. While that has many investors optimistic on the future of EV and specifically on Rivian, why don’t they see the competition that’s coming down the pike?\nIt would be one thing if Rivian was going to enter the electric pickup truck market with no competition. But the fact that it’s fighting the electrification of the country’s best-selling pickup and vehicle,andgoing up againstTesla(NASDAQ:TSLA), GM and others, should have investors asking some questions.\nNamely this: Is RIVN stock overvalued or is F stock undervalued — or is it both?\nGranted, the R1T has a better EPA-estimated driving range for its base model than the base model for Ford’s Lightning. That said, Ford’s electric pickup starts at around $40,000 and can get an upgrade to its range, while the R1T has a starting price of roughly $67,500.\nFord expects to “increase its production capacity of electric vehicles to 600,000 units globally by 2023.” Further, CEO Jim Farley “expects that would make the company the second-largest U.S.-based producer of EVs,” just behind Tesla(NASDAQ:TSLA).\nFor what it’s worth, General Motors will likely be in that mix as well, with management previously stating it expects to produce 1 million EVs by 2025.\nBottom Line on RIVN Stock\nI must repeat again that I don’t have anything personal against Rivian. I actually really like EVs and autonomous driving systems and I covered the space for years.\nBut the sudden fascination with this industry — shown via the valuations — has me asking some questions as to how it’s justified. For now, I still don’t have the answer and, between the two stocks, I’d rather be long Ford at these levels than RIVN stock.","news_type":1},"isVote":1,"tweetType":1,"viewCount":440,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}